Time to onset of reported AEs. حسب Lingling Wu (411099)

الموضوعات:

Respondents’ knowledge of ADRs and their reporting. حسب Wajiha Iffat (5830562)

الموضوعات:

Segmented regression analysis of time to intravenous antimicrobial administration (IVA) at intervention and control sites during the implementation period. حسب J Mark Ansermino (13958512)

الموضوعات:

Interrupted time series analysis showing time to intravenous antimicrobials (IVA) in minutes at intervention and control sites in Uganda during baseline and implementation periods. حسب J Mark Ansermino (13958512)

الموضوعات:

Kenya: Enrolment, time to IVA, mortality, admissions and readmissions at sites in Kenya. حسب J Mark Ansermino (13958512)

الموضوعات:

Uganda: enrolment, time to IVA, mortality, admissions and readmissions. حسب J Mark Ansermino (13958512)

الموضوعات:

Interrupted time series analysis showing time to intravenous antimicrobials (IVA) in minutes at intervention and control sites in Kenya during baseline and implementation periods. حسب J Mark Ansermino (13958512)

الموضوعات:

Bluetooth beacons with colour coded lanyards. حسب J Mark Ansermino (13958512)

الموضوعات:

Flow diagram of the Smart Triage multisite interventional study in Uganda and Kenya indicating the progress through study phases at each site. حسب J Mark Ansermino (13958512)

الموضوعات:

Male and female self-reported compliance of mouthguard use (n = 545). <i>*: Significant difference between males and females at p < 0.05.</i> حسب Aoife Burke (11421863)

الموضوعات:

Longitudinal tracking of self-reported CVD outcomes in the WSCS database. حسب Duy Nguyen (1831585)

Lymphocyte proliferation assay following combination therapy with NDV. حسب Hedieh Zargaran (21410233)

Tumor volume measurements. حسب Hedieh Zargaran (21410233)

The most significant biomarker from the analyzed datasets. حسب Jibon Kumar Paul (19704476)

الموضوعات:

PPI network analysis. حسب Du Leng (20421711)

IL-10 levels in tumor lysates post-treatment. حسب Hedieh Zargaran (21410233)

Table 1_Case Report: Novel treatment approach for severe interstitial lung disease in type 3 Gaucher disease.docx حسب Vincenza Gragnaniello (13847017)

"…Pulmonary manifestations can significantly impact prognosis and quality of life. This case report highlights the challenges in managing severe pulmonary involvement in GD and explores novel treatment approaches. …"

Median ± IQR <i>M. plutonius</i> bacterial load (CFU/bee) of newly emerged summer worker bees inoculated with 1 × 10⁷ CFU/bee <i>M. plutonius</i> 2019BC1 and/or treated... حسب Midhun Sebastian Jose (19336846)

Supplementary Material for: Biotin-Thiamine-Responsive Basal Ganglia Disease Case report حسب Tse J. (20373048)

"…Diagnosis relies on the identification of biallelic pathogenic variants in the SLC19A3 gene. This case report describes two novel variants of uncertain significance in the SLC19A3 gene, which may be correlated with the phenotypic manifestations of BTBGD. …"

Supplementary Material for: Darier’s Disease Successfully Treated with Tofacitinib: A Case Report حسب figshare admin karger (2628495)

"…The patient was then started on tofacitinib 10 mg daily, leading to disease stabilization. Due to persistent itching and new lesions, the dose was increased to 15 mg daily, resulting in significant improvement. …"